Your shopping cart is currently empty

Lumicitabine (ALS-008176) is an RSV polymerase inhibitor.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | $347 | 7-10 days | 7-10 days | |
| 10 mg | $541 | 7-10 days | 7-10 days | |
| 1 mL x 10 mM (in DMSO) | $329 | 7-10 days | 7-10 days |
| Description | Lumicitabine (ALS-008176) is an RSV polymerase inhibitor. |
| In vivo | In an adult human challenge study, Lumicitabine has shown efficacy against RSV infection[1]. Lumicitabine solubility is adequate to support oral administration in solutions with a relatively low percentage of organic solvent and in aqueous suspensions. High levels of NMP and NTP are obtained following the oral administration of Lumicitabine to monkeys [2]. |
| Animal Research | Rats: Lumicitabine is formulated as solutions in PEG400-based vehicles. Pharmacokinetic studies are conducted at 5 mg/kg and for oral PK studies, the prodrugs are administered at 5 mg/kg parent nucleoside equivalent doses. Blood samples are typically collected at various time points up to 24 h post dose for rat [2]. Monkeys: Lumicitabine is formulated as a solution in PEG400-based vehicles. Pharmacokinetic studies are conducted at 5 mg/kg and for oral PK studies, the prodrugs are administered at 5 mg/kg parent nucleoside equivalent doses. Blood samples are typically collected at various time points up to 12 h post dose for Monkeys [2]. |
| Synonyms | ALS-8176, ALS-008176 |
| Molecular Weight | 433.86 |
| Formula | C18H25ClFN3O6 |
| Cas No. | 1445385-02-3 |
| Smiles | CC(C)C(=O)OC[C@@]1(CCl)O[C@H]([C@H](F)[C@@H]1OC(=O)C(C)C)n1ccc(N)nc1=O |
| Relative Density. | 1.43 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 48 mg/mL (110.63 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 2 mg/mL (4.61 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.